Mereo BioPharma Group plc
As of Oct 22, 2026, Mereo BioPharma Group is in Stage 1, the basing phase, now in week 3 (since Oct 6, 2026). It closed at $0.29, 87.6% below its 52-week high and below its 200-day average, which is falling.
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is MREO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
MREO among Biotechnology502nd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …502 | MREO | Stage 1 · wk 3 | 8 | −15.6% |
Mereo BioPharma Group: quick answers
What stage is Mereo BioPharma Group in?
As of Oct 22, 2026, Mereo BioPharma Group (MREO) is in Stage 1, the basing phase. It entered Stage 1 on Oct 6, 2026 and is in week 3. What the four stages mean
Is Mereo BioPharma Group in an uptrend?
Not yet. Mereo BioPharma Group is in Stage 1, a base that can come before an uptrend. It trades 15.8% below its 200-day average, which is falling.
How far is Mereo BioPharma Group from its 52-week high?
Mereo BioPharma Group closed at $0.29 on Oct 22, 2026, 87.6% below its 52-week high of $2.31. Its 52-week low is $0.24.
How has Mereo BioPharma Group performed over the past year?
As of Oct 22, 2026, Mereo BioPharma Group is down 86.5% over the past year and down 43.7% so far in 2026.
Which sector and industry is Mereo BioPharma Group in?
Mereo BioPharma Group is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.